Investigating Biomarkers in Acute Respiratory Distress Syndrome
The ASSESSMENT of SERPINB3 EXPRESSION, PAR2 and SCCA-PD POLYMORPHISM in PATIENTS with ACUTE RESPIRATORY DISTRESS SYNDROME
This study is trying to see if certain markers in the blood can help us understand how Acute Respiratory Distress Syndrome affects the lungs and how severe the condition is in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Padova Academic / other |
| Locations | 1 site (Padova, PD) |
| Trial ID | NCT06774534 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with Acute Respiratory Distress Syndrome (ARDS) and aims to explore the expression of SERPINB3 and the polymorphism SCCA-PD, as well as the role of protease-activated receptor 2 (PAR2) in the disease's pathophysiology. By conducting a detailed clinical and biomolecular phenotyping, the study seeks to uncover new insights into the mechanisms of lung injury associated with ARDS. The research will analyze how these biomarkers correlate with the severity of lung injury and inflammation in affected patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with ARDS who require invasive mechanical ventilation.
Not a fit: Patients under 18 years, pregnant individuals, or those with chronic inflammatory skin conditions or chronic lung diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to personalized treatment strategies for ARDS patients based on their specific biomolecular profiles.
How similar studies have performed: While the specific approach of studying SERPINB3 and PAR2 in ARDS is novel, similar studies have shown promise in understanding biomarkers in other respiratory conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ARDS DIAGNOSIS * IMV Exclusion Criteria: * Age under 18 years * Pregnancy status * Lack of consent to participate in the study * Contraindications to fiberoptic bronchoscopy and/or BAL (bronchoalveolar lavage) * Patients with chronic inflammatory skin conditions * Patients with chronic lung diseases * Patients with inflammatory respiratory diseases * Patients with neoplasms such as: squamous cell carcinoma of the cervix, squamous cell carcinoma of the esophagus, lung adenocarcinoma, breast adenocarcinoma, pancreatic adenocarcinoma, hepatocellular carcinoma * History of active or passive smoking
Where this trial is running
Padova, PD
- Azienda Ospedaliera di Padova — Padova, Pd, Italy (Recruiting)
Study contacts
- Study coordinator: Annalisa Boscolo, Professor
- Email: annalisa.boscolo@gmail.com
- Phone: +393498324972
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.